Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.33 |
| ▸ | HTR3B | O95264 | 3/20 | 0.33 |
| ▸ | HTR3A | P46098 | 3/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066449 | 0.73 | ADRB1 (0.38) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1420015 | 0.64 | ADRB1 (0.36) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27262548 | 0.62 | HTR3A (0.35) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1248486 | 0.62 | ADRB1 (0.45) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28793521 | 0.62 | — | — | |
| SCHEMBL28812166 | 0.62 | MAPT (0.31) | ALDH1A1 | |
| SCHEMBL4421139 | 0.62 | ADRB2 (0.36) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4421143 | 0.62 | ADRB2 (0.40) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Iodide SCHEMBL28159118 | 0.60 | — | — | |
| Water SCHEMBL28159507 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607129-B1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH SA (BE) | 1995-08-23 | — | — | EP | claimed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | claimed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | claimed |
| WO-1993007143-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH S.A./N.V. (BE) | 1993-04-15 | — | — | WO | claimed |
| EP-1593676-B1 | 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor | CAMH (CA) | 2009-10-07 | — | — | EP | disclosed |
| US-20090149442-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ | 2009-06-11 | — | — | US | disclosed |
| EP-1696931-B1 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARM INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1406881-B1 | 11-PIPERAZINYLDIBENZO(B,F)(1,4)OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR | NEUROMOLECULAR INC (CA) | 2006-09-13 | — | — | EP | disclosed |
| US-20060166965-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ | 2006-07-27 | — | — | US | disclosed |
| EP-1593676-A1 | 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor | Neuromolecular, Inc. (CA) | 2005-11-09 | — | — | EP | disclosed |
| US-20050222121-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ | 2005-10-06 | — | — | US | disclosed |
| US-6890919-B2 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ (CA) | 2005-05-10 | — | — | US | disclosed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | disclosed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | disclosed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | disclosed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | disclosed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | disclosed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007143-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH S.A./N.V. (BE) | 1993-04-15 | — | — | WO | disclosed |
| WO-1993007143-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH S.A./N.V. (BE) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149442-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | DRD2, OPRD1, GRIN2A | ADRB1 112/4885HTR3E 155/4885HTR3B 19/4885 |
| US-20050222121-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | DRD2, OPRD1, GRIN2A | ADRB1 112/4885HTR3E 155/4885HTR3B 19/4885 |
| US-20060166965-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | DRD2, OPRD1, GRIN2A | ADRB1 112/4885HTR3E 155/4885HTR3B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.